Clinical Trials Logo
  1. Home
  2. Hypertension
  3. NCT03231293
  4. Details
NCT03231293 Clinical Trial

Fimasartan Blood Pressure Lowering After Acute Stroke

Hypertension Clinical Trial

— FABULOUS  

Official title:
A Multicenter Longitudinal Observational Study to Assess the Effectiveness of Fimasartan-based Antihypertensive Treatment and Prognosis in Post-Acute Phase of Ischemic Stroke or Transient Ischemic Attack

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT03231293
Other study ID # BR-FMS-OS-401
Secondary ID
Status Completed
Phase
First received
Last updated
Start date July 28, 2016
Est. completion date April 5, 2019

Study information
Verified date November 2019
Source Boryung Pharmaceutical Co., Ltd
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study evaluates the effectiveness of fimasartan-based antihypertensive treatment and prognosis in post-acute phase of ischemic stroke or transient ischemic attack patients. All participants will receive fimasartan, and the investigators will follow them up for 6 months.

Recruitment information / eligibility
Status Completed
Enrollment 1035
Est. completion date April 5, 2019
Est. primary completion date November 2, 2018
Accepts healthy volunteers No
Gender All
Age group 19 Years and older
Eligibility Inclusion Criteria:

- Ischemic stroke or transient ischemic attack occurs after 7 days to 3 months.

- Mean blood pressure measured 3 times at the first visit (Visit 1) should be over 140 mmHg for systolic blood pressure or 90 mmHg for diastolic blood pressure

- Suitable for administration of fimasartan

- The life expectancy should be over 6 months.

Exclusion Criteria:

- Patients already treated with antihypertensive medications

- Hemorrhagic stroke patients

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
Korea, Republic of Korea University Ansan Hospital Ansan
Korea, Republic of Hallym University Medical Center Anyang
Korea, Republic of Dong-A University Hospital Busan
Korea, Republic of Inje University Busan Paik Hospital Busan
Korea, Republic of Pusan National University Hospital Busan
Korea, Republic of Keimyung University Dongsan Medical Center Daegu
Korea, Republic of Kyungpook National University Hospital Daegu
Korea, Republic of Daejeon Eulji Medical Center Daejeon
Korea, Republic of Inje University Ilsan Paik Hospital Goyang
Korea, Republic of Myongji Hospital Goyang
Korea, Republic of Chonnam National University Hospital Gwangju
Korea, Republic of Chosun University Hospital Gwangju
Korea, Republic of Inha University Hospital Incheon
Korea, Republic of Jeju National University Hospital Jeju
Korea, Republic of Seoul National University Bundang Hospital Seongnam
Korea, Republic of Asan Medical Center Seoul
Korea, Republic of Ewha Womans University Medical Center Seoul
Korea, Republic of Gangnam Severance Hospital Seoul
Korea, Republic of Inje University Sanggye Paik Hospital Seoul
Korea, Republic of Kyunghee University Medical Center Seoul
Korea, Republic of Nowon Eulji Medical Center, Eulji University Seoul
Korea, Republic of Samsung Medical Center Seoul
Korea, Republic of Seoul National University Boramae Medical Center Seoul
Korea, Republic of Seoul St. Mary's Hospital Seoul
Korea, Republic of Severance Hospital, Yonsei University Health System Seoul
Korea, Republic of Soonchunhyang University Hospital Seoul
Korea, Republic of Ulsan University Hospital Ulsan

Sponsors (1)
Lead Sponsor Collaborator
Boryung Pharmaceutical Co., Ltd

Country where clinical trial is conducted

Korea, Republic of, 

Outcome
Type Measure Description Time frame Safety issue
Primary BP Blood pressure control rate(<140/90 mmHg) 24 weeks
Secondary BP Blood pressure control rate(<140/90 mmHg) 4, 12 weeks
Secondary BP Blood pressure changes 4, 12, 24 weeks
Secondary mRS mRS changes 4, 12, 24 weeks
Secondary Fimasartan-based treatment Fimasartan-based treatment modalities 24 weeks
Secondary Fimasartan starting point Fimasartan starting point after stroke 24 weeks
Secondary Stroke recurrence Rate of stroke recurrence 24 weeks
Secondary Cardiovascular events Incidence of cardiovascular events 24 weeks
Secondary Mortality rates from cardiovascular disease Mortality rates from cardiovascular disease 24 weeks
Secondary Mortality rates of any cause Mortality rates of any cause 24 weeks
Secondary Adverse events Adverse events related to antihypertensive treatments 24 weeks
See also
  Status Clinical Trial Phase
Terminated NCT04591808 - Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia Phase 3
Recruiting NCT04515303 - Digital Intervention Participation in DASH
Completed NCT05433233 - Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension N/A
Completed NCT05491642 - A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses Phase 1
Completed NCT03093532 - A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT05529147 - The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
Recruiting NCT05976230 - Special Drug Use Surveillance of Entresto Tablets (Hypertension)
Recruiting NCT06363097 - Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
Completed NCT06008015 - A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers Phase 1
Completed NCT05387174 - Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period N/A
Completed NCT04082585 - Total Health Improvement Program Research Project
Recruiting NCT05121337 - Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension N/A
Withdrawn NCT04922424 - Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men Phase 1
Active, not recruiting NCT05062161 - Sleep Duration and Blood Pressure During Sleep N/A
Not yet recruiting NCT05038774 - Educational Intervention for Hypertension Management N/A
Completed NCT05087290 - LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR)
Completed NCT05621694 - Exploring Oxytocin Response to Meditative Movement N/A
Completed NCT05688917 - Green Coffee Effect on Metabolic Syndrome N/A
Recruiting NCT05575453 - OPTIMA-BP: Empowering PaTients in MAnaging Blood Pressure N/A